The studies showed that the administration of AMD3100 (CXCL12 inhibitor) induced rapid T-cell accumulation in the region of tumor-containing cancer cells and performed synergistically with α-programmed cell death 1 ligand 1 (α-PD-L1) to greatly induce the apoptosis of cancer cells. Here, CXCL12 is linked to cancer.